secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0000950170-25-019314
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA reports Q4 2024 net loss of $130.3M; cash ~$1.1B, funds operations into at least 2028
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities of ~$1.1B as of Dec 31, 2024, up from $632.6M in 2023.
- Net loss for Q4 2024 was $130.3M vs $34.0M in Q4 2023; full-year net loss $274.5M vs $113.0M.
- R&D expenses surged to $140.2M in Q4 2024 from $38.8M, driven by $75M upfront for IDE849 license from Hengrui.
- Over 230 patients enrolled in darovasertib + crizotinib Phase 2/3 in 1L HLA-A2-negative MUM; median PFS readout by year-end 2025.
- Announced three development candidates: IDE892 (PRMT5), IDE034 (B7H3/PTK7 ADC), IDE251 (KAT6/7); INDs targeted in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017025019314/0000950170-25-019314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017025019314/idya-20250213.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-019314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer